{"id":1117,"date":"2026-10-08T06:34:31","date_gmt":"2026-10-08T06:34:31","guid":{"rendered":"https:\/\/genes2me.com\/blog\/?p=1117"},"modified":"2026-10-08T07:48:22","modified_gmt":"2026-10-08T07:48:22","slug":"breast-cancer-molecular-testing","status":"publish","type":"post","link":"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/","title":{"rendered":"Breast Cancer Awareness Month: Advancing Precision Testing Through Molecular Diagnostics"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

It’s Breast Cancer Awareness Month, and we’re looking beyond awareness alone, toward the molecular insights that can support earlier risk assessment, better disease characterization, and more informed clinical decision-making.<\/p>\n\n\n\n

Breast cancer is not a single disease. Differences in inherited and acquired genetic alterations, homologous recombination status, and tumor evolution can influence both risk and treatment strategy. As precision oncology continues to evolve, molecular testing has become an increasingly important part of understanding these differences.<\/p>\n\n\n\n

At Genes2Me, our oncology portfolio brings together Next-Generation Sequencing (NGS) panels<\/a> <\/strong>and targeted Real-Time PCR testing<\/a><\/strong> to support different molecular testing needs across breast cancer care. From comprehensive genomic profiling and BRCA1\/2 assessment to HRD evaluation and liquid biopsy-based monitoring, these technologies provide complementary approaches to clinically relevant molecular information.<\/p>\n\n\n\n

This Breast Cancer Awareness Month<\/strong>, we’re highlighting how Genes2Me molecular assays can support laboratories, oncologists, pathologists, and genetic counsellors in bringing precision testing closer to clinical decision-making.<\/p>\n\n\n\n

Why Breast Cancer Needs More Than One Molecular Approach<\/strong><\/p>\n\n\n\n

Breast cancer is one of the most commonly diagnosed cancers in the world. Mammography and clinical screening have done a lot to improve survival by catching disease early, but another layer of information can be gained by understanding the molecular characteristics of cancer and inherited risk.<\/p>\n\n\n\n

Breast cancer can involve germline variants, somatic alterations, genomic instability, and acquired resistance mechanisms<\/strong>, making molecular testing an important part of modern precision oncology.<\/p>\n\n\n\n

Different testing technologies can address different molecular questions. NGS enables broader genomic profiling across multiple genes and alteration types<\/strong>, while targeted Real-Time PCR can provide focused detection of specific clinically relevant variants<\/strong>.<\/p>\n\n\n\n

Rather than replacing one another, these approaches can form part of a complementary molecular testing strategy \u2014 depending on the clinical question, variants of interest, sample type, and testing requirements.<\/p>\n\n\n\n

1. The Genes2Me BRCA 1\/2 NGS Assay<\/a>: <\/strong>Germline and Somatic Screening<\/strong><\/p>\n\n\n\n

Mutations in the BRCA1 and BRCA2<\/strong> tumor suppressor genes explain a large share of hereditary breast and ovarian cancers. They also matter when choosing treatment for somatic tumors.<\/p>\n\n\n\n

The Genes2Me BRCA 1\/2 NGS Assay<\/strong> provides comprehensive assessment of BRCA1 and BRCA2 across the whole coding sequence and promoter regions, enabling detection of multiple classes of genomic alterations.<\/p>\n\n\n\n

Genes Covered<\/strong><\/td>Covered Region<\/strong><\/td>Target Size<\/strong><\/td>Mutation Types<\/strong><\/td>Sample Types<\/strong><\/td>Targeted Therapies<\/strong><\/td>Assay Uniformity<\/strong><\/td><\/tr>
2 (BRCA1 and BRCA2)<\/td>Whole CDS (+\/-40bp) and promoter regions<\/td>0.02 Mb<\/td>SNVs, InDels, CNVs, Rearrangements<\/td>Blood (Germline) & FFPE Tissue (Somatic)<\/td>PARP Inhibitors: Olaparib, Talazoparib<\/td>>99% Coverage Uniformity @ 0.2X<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Key Clinical Advantages<\/strong><\/p>\n\n\n\n

\u25cf Full coding region and promoter coverage:<\/strong> The assay covers the whole coding sequence and promoter regions, enabling detection of SNVs, small insertions and deletions (InDels), copy number variations (CNVs), and structural rearrangements.<\/p>\n\n\n\n

\u25cf Therapy matching:<\/strong> BRCA status can contribute to treatment decision-making, including consideration of targeted therapies such as PARP inhibitors in appropriate clinical contexts.<\/p>\n\n\n\n

\u25cf Efficiency and uniformity:<\/strong> Coverage is highly uniform, supporting consistent sequencing performance while reducing coverage bias.<\/p>\n\n\n\n

When Targeted BRCA Testing Is the Question<\/strong><\/p>\n\n\n\n

While NGS provides broad genomic information and can identify multiple classes of BRCA alterations, not every testing requirement calls for a comprehensive sequencing panel.<\/p>\n\n\n\n

For laboratories and clinical settings where the objective is focused detection of specific BRCA1 and BRCA2 variants<\/strong>, a targeted Real-Time PCR approach can provide a complementary testing option.<\/p>\n\n\n\n

2<\/strong>. The Genes2Me BRCA-Q Real-Time PCR Kit: Targeted Detection of BRCA1\/2 Variants<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

BRCA1 and BRCA2 variants are important biomarkers in hereditary breast and ovarian cancer risk assessment. Identifying specific pathogenic variants can support risk stratification, preventive care, family counselling, and clinical management.<\/p>\n\n\n\n

The Genes2Me BRCA-Q Real-Time PCR Kit<\/strong> is a CE-IVD qualitative in vitro diagnostic assay designed for the detection and allelic differentiation of eight specified BRCA1 and BRCA2 genetic polymorphisms<\/strong> associated with breast and ovarian cancer.<\/p>\n\n\n\n

The assay detects seven BRCA1 variants and one BRCA2 variant<\/strong>:<\/p>\n\n\n\n

BRCA1:<\/strong> 185delAG, 4153delA, 5382insC, 3819delGTAAA, 3875delGTCT, 300T>G (Cys61Gly), 2080delA
BRCA2:<\/strong> 6174delT<\/p>\n\n\n\n

Targeted Testing Through Real-Time PCR<\/strong><\/p>\n\n\n\n

BRCA-Q uses Real-Time PCR with melting curve analysis<\/strong> and allele-specific fluorescent probes to distinguish wild-type and mutant alleles.<\/p>\n\n\n\n

Following amplification, melting curve analysis evaluates the melting temperature (Tm) of the probe\u2013amplicon complexes. Differences in Tm allow discrimination between wild-type and mutant allelic variants, including heterozygous samples.<\/p>\n\n\n\n

The built-in internal control<\/strong> helps verify DNA input, reagent integrity, and PCR performance, with a Ct cut-off of \u226432 for a valid result.<\/p>\n\n\n\n

Key Features of BRCA-Q<\/strong><\/p>\n\n\n\n

\u25cf Eight specified BRCA variants:<\/strong> Detects and differentiates seven BRCA1 variants and one BRCA2 variant.<\/p>\n\n\n\n

\u25cf Three-channel multiplex design:<\/strong> Enables simultaneous assessment of wild-type allele, mutant allele, and internal control.<\/p>\n\n\n\n

\u25cf Melting curve-based allelic discrimination:<\/strong> Supports differentiation of wild-type and mutant variants based on distinct melting temperatures.<\/p>\n\n\n\n

\u25cf High analytical and clinical performance:<\/strong> The assay demonstrates 100% analytical sensitivity and specificity, 99% accuracy, and 99% clinical sensitivity and specificity.<\/p>\n\n\n\n

\u25cf Low detection limit:<\/strong> Detects as little as 1 genome equivalent per 1.0 ng of human DNA per reaction.<\/p>\n\n\n\n

\u25cf Built-in quality control:<\/strong> The internal control helps confirm DNA input and PCR validity for every run.<\/p>\n\n\n\n

\u25cf Platform flexibility:<\/strong> Validated on Thermo Fisher QuantStudio 5, Bio-Rad CFX96, Roche LightCycler 480, and Genes2Me RapiCycler 96 platforms.<\/p>\n\n\n\n

NGS or Targeted RT-PCR? Choosing the Right Molecular Approach<\/strong><\/p>\n\n\n\n

The two approaches address related but distinct testing needs.<\/p>\n\n\n\n

BRCA 1\/2 NGS Assay<\/strong>
Best suited to broader BRCA assessment, with coverage extending across the coding and promoter regions and the ability to identify multiple alteration types, including SNVs, InDels, CNVs, and rearrangements.<\/p>\n\n\n\n

BRCA-Q Real-Time PCR Kit<\/strong>
Designed for focused detection and allelic differentiation of eight specified BRCA1\/2 variants using a targeted Real-Time PCR workflow.<\/p>\n\n\n\n

Together, they illustrate how different molecular technologies can support different testing strategies within precision breast cancer diagnostics \u2014 from broader genomic characterization to targeted variant detection<\/strong>.<\/p>\n\n\n\n

3. Looking Past BRCA: The CancerCheck Core (HRD Assay)<\/strong><\/p>\n\n\n\n

BRCA1\/2 mutations are a well-known cause of Homologous Recombination Deficiency (HRD), but many breast cancer patients show an HRD phenotype even without a detectable BRCA mutation. This pattern is often called BRCAness. Finding these patients matters because it can open up PARP inhibitors and platinum-based chemotherapy to people who might otherwise miss out.<\/p>\n\n\n\n

The Genes2Me CancerCheck Core (HRD Assay)<\/strong> is a targeted hybridization-capture NGS panel that looks at more than 51,000 genome-wide Single Nucleotide Polymorphisms (SNPs)<\/strong> and also covers the whole coding sequence of BRCA1 and BRCA2.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Key Highlights<\/strong><\/p>\n\n\n\n

\u25cf Genomic Scar Score (GSS):<\/strong> Measures genomic instability using three markers: Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-Scale Transitions (LST).<\/strong><\/p>\n\n\n\n

\u25cf Clear cutoff:<\/strong> A combined GSS of \u226542, calculated in the CliSeq Interpreter<\/a><\/strong> platform, classifies a tumor as HRD-positive, which can inform treatment decisions in the appropriate clinical context.<\/p>\n\n\n\n

\u25cf One run:<\/strong> A single library preparation provides both BRCA1\/2 variant information and genomic scar indicators.<\/p>\n\n\n\n

\u25cf Performance:<\/strong> Shows 99% sensitivity with matched tumor\/normal samples and 99% concordance with reference standards.<\/p>\n\n\n\n

4. <\/strong>Tracking the Disease Over Time: ctDNA Breast Liquid Biopsy Assay<\/a><\/strong><\/p>\n\n\n\n

Tissue biopsies can be invasive, difficult to repeat, and may not capture the full molecular heterogeneity of a tumor. Circulating tumor DNA (ctDNA) liquid biopsy provides a less invasive approach for monitoring molecular changes over time.<\/p>\n\n\n\n

The Genes2Me ctDNA Breast Assay<\/strong> screens 63 clinically relevant genes<\/strong>, including 14 key DNA fusions, using cell-free DNA (cfDNA) from blood plasma.<\/p>\n\n\n\n

Assay Parameter<\/strong><\/td>Specification & Coverage Details<\/strong><\/td><\/tr>
Target Size<\/strong><\/td>440 kb<\/td><\/tr>
Input Requirement<\/strong><\/td>10\u201320 ng cfDNA<\/td><\/tr>
Key Genes Covered<\/strong><\/td>BRCA1, BRCA2, ESR1, PIK3CA, ERBB2 (HER2), AKT1, ATM, CDH1, GATA3, PTEN, PALB2, RB1, TP53, and more<\/td><\/tr>
Target DNA Fusions<\/strong><\/td>CCDC170, CD74, ESR1, ETV6, NTRK1, NTRK3, TPM3, etc.<\/td><\/tr>
Clinical Utilities<\/strong><\/td>Minimal Residual Disease (MRD), Treatment Resistance, Therapy Selection, Disease Recurrence Tracking<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Actionable Clinical Insights<\/strong><\/p>\n\n\n\n

\u25cf Resistance mutations:<\/strong> Picks up acquired resistance variants such as ESR1 and PIK3CA mutations, which can inform treatment considerations in appropriate clinical settings.<\/p>\n\n\n\n

\u25cf HER2 \/ ERBB2 alteration tracking:<\/strong> Follows ERBB2 amplification to support assessment of HER2-related molecular alterations.<\/p>\n\n\n\n

\u25cf Capture efficiency:<\/strong> More than 75% of reads align on target even from low-input cfDNA (10\u201320 ng), supporting variant calling at low Variant Allele Frequencies (VAF).<\/p>\n\n\n\n

5. <\/strong>Other Panels That Include BRCA<\/strong><\/p>\n\n\n\n

If broader somatic profiling or germline screening is required, BRCA1 and BRCA2 are also included in several of our multi-gene panels:<\/p>\n\n\n\n

Panel Name<\/strong><\/td>Genes<\/strong><\/td>Primary Clinical Application<\/strong><\/td><\/tr>
PanCan CGP Assay<\/strong><\/td>774 DNA \/ 105 RNA<\/td>Comprehensive Genomic Profiling; covers TMB, MSI, HRD score option, SNVs, InDels, CNVs, and fusion breakpoints.<\/td><\/tr>
Common Hereditary Cancer NGS Assay<\/strong><\/td>83 Genes<\/td>Germline risk screening covering BRCA1, PLB2, CHEK2, ATM, CH1, TP53, PTEN, STK11, and mismatch repair genes.<\/td><\/tr>
OncoCheck Assay (HRR Focused)<\/strong><\/td>~53 Genes<\/td>Target-enriched panel evaluating key HRR pathway genes and actionable somatic\/germline biomarkers.<\/td><\/tr>
CancerCheck 50 Assay<\/strong><\/td>~67 Genes<\/td>Cost-effective targeted screening of primary cancer hotspots and driver alterations.<\/td><\/tr>
CancerCheck 100 Assay<\/strong><\/td>148 Genes<\/td>Broad somatic\/germline profiling including MSI status and comprehensive HRR pathways.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

6. From Sample to Report: Building a Molecular Testing Workflow<\/strong><\/p>\n\n\n\n

Genes2Me’s molecular testing portfolio is designed to support different laboratory workflows \u2014 from targeted Real-Time PCR testing to comprehensive NGS-based genomic profiling.<\/p>\n\n\n\n

For NGS testing, our workflow is built to cut down on manual handling, shorten turnaround times, and keep results accurate from start to finish.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
  1. Hybridization capture:<\/strong> Probe design delivers >99% coverage uniformity with a low fold-80 base penalty, supporting efficient sequencing and sensitivity.<\/li>
  2. Works with your sequencer:<\/strong> The kits are compatible with major sequencing platforms, including Illumina\u00ae, MGI\u00ae, Thermo Fisher\u00ae (Ion Torrent), and Element Biosciences\u00ae (AVITI)<\/strong>.<\/li>
  3. Automated library prep:<\/strong> Runs on the EZY-AutoPrep Workstation<\/a><\/strong> with 24\/48\/96-sample throughput, reducing hands-on time and handling-related variability.<\/li>
  4. Automated analysis with CliSeq Interpreter:<\/strong> This cloud-based or on-site tertiary analysis pipeline converts raw FASTQ files into annotated Clinically Significant Mutation (CSM) reports in under an hour, with reporting aligned with ACMG, ASCO, NCCN, and AMP<\/strong> guidelines.<\/li><\/ol>\n\n\n\n

    For targeted BRCA testing, BRCA-Q provides a focused Real-Time PCR workflow<\/strong> with allele-specific detection, melting curve analysis, and an integrated internal control, validated across leading Real-Time PCR platforms.<\/p>\n\n\n\n

    Bringing Molecular Insights Together<\/strong><\/p>\n\n\n\n

    Breast cancer precision testing is not defined by a single technology. The molecular question determines the testing approach.<\/p>\n\n\n\n

    Need comprehensive BRCA characterization?<\/strong> The Genes2Me BRCA 1\/2 NGS Assay provides broad coverage and detection of multiple alteration types.<\/p>\n\n\n\n

    Need targeted detection of specified BRCA variants?<\/strong> The BRCA-Q Real-Time PCR Kit provides focused qualitative detection and allelic differentiation of eight specified BRCA1\/2 variants.<\/p>\n\n\n\n

    Need to assess genomic instability beyond BRCA?<\/strong> CancerCheck Core evaluates genome-wide SNPs and BRCA1\/2 to calculate an HRD Genomic Scar Score.<\/p>\n\n\n\n

    Need to monitor molecular changes over time?<\/strong> The ctDNA Breast Assay provides a liquid biopsy approach for assessing clinically relevant alterations, resistance, and disease evolution.<\/p>\n\n\n\n

    Need broader genomic profiling?<\/strong> Genes2Me’s multi-gene oncology panels extend testing across a wider range of biomarkers and cancer-associated genes.<\/p>\n\n\n\n

    Together, these approaches support a broader vision of precision breast cancer testing \u2014 matching the molecular question with the appropriate testing technology.<\/strong><\/p>\n\n\n\n

    Talk to Us About Precision Breast Cancer Testing<\/a><\/strong><\/p>\n\n\n\n

    This Breast Cancer Awareness Month, Genes2Me is committed to supporting laboratories and clinicians with molecular testing solutions that can turn genetic information into clinically meaningful insights.<\/p>\n\n\n\n

    From targeted BRCA1\/2 variant detection with BRCA-Q<\/strong> to comprehensive genomic profiling, HRD assessment, and ctDNA-based molecular monitoring<\/strong>, our portfolio brings together complementary technologies for different stages and requirements of precision oncology.<\/p>\n\n\n\n

    Explore our oncology portfolio and find the testing approach that fits your laboratory’s needs.<\/p>\n\n\n\n

    \u25cf Explore Our Oncology Portfolio:<\/strong> www.genes2me.com<\/a><\/p>\n\n\n\n

    \u25cf Request a Panel Demonstration or Gene List:<\/strong> Contact our technical team at contact@genes2me.com<\/a> or call toll-free at +91 18001 214030.<\/p>\n","protected":false},"excerpt":{"rendered":"

    It’s Breast Cancer Awareness Month, and we’re looking beyond awareness alone, toward the molecular insights that can support earlier risk assessment, better disease characterization, and…<\/p>\n","protected":false},"author":1,"featured_media":1125,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[512],"tags":[515,516,514,513,517],"yoast_head":"\nBreast Cancer Molecular Testing: NGS, BRCA & HRD<\/title>\n<meta name=\"description\" content=\"Explore breast cancer molecular testing with NGS, BRCA1\/2, HRD assessment and ctDNA liquid biopsy for precision oncology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Breast Cancer Molecular Testing: NGS, BRCA & HRD\" \/>\n<meta property=\"og:description\" content=\"Explore breast cancer molecular testing with NGS, BRCA1\/2, HRD assessment and ctDNA liquid biopsy for precision oncology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/\" \/>\n<meta property=\"og:site_name\" content=\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-08T06:34:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-08T07:48:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2026\/10\/Breast-Cancer-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"525\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Genes2Me\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Genes2Me\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\",\"name\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\",\"url\":\"https:\/\/genes2me.com\/blog\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg\",\"contentUrl\":\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg\",\"width\":150,\"height\":69,\"caption\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\"},\"image\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/genes2me.com\/blog\/#website\",\"url\":\"https:\/\/genes2me.com\/blog\/\",\"name\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\",\"description\":\"Real Time PCR Molecular Diagnostics NGS Cancer Screening Sequencing COVID-19 Rapid Antigen Antibody Made in India Manufacturer Clinical\/Whole Exome\",\"publisher\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/genes2me.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/\",\"url\":\"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/\",\"name\":\"Breast Cancer Molecular Testing: NGS, BRCA & HRD\",\"isPartOf\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#website\"},\"datePublished\":\"2026-10-08T06:34:31+00:00\",\"dateModified\":\"2026-10-08T07:48:22+00:00\",\"description\":\"Explore breast cancer molecular testing with NGS, BRCA1\/2, HRD assessment and ctDNA liquid biopsy for precision oncology.\",\"breadcrumb\":{\"@id\":\"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/genes2me.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Breast Cancer Awareness Month: Advancing Precision Testing Through Molecular Diagnostics\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/\"},\"author\":{\"name\":\"Genes2Me\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa\"},\"headline\":\"Breast Cancer Awareness Month: Advancing Precision Testing Through Molecular Diagnostics\",\"datePublished\":\"2026-10-08T06:34:31+00:00\",\"dateModified\":\"2026-10-08T07:48:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/\"},\"wordCount\":1825,\"publisher\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\"},\"keywords\":[\"BRCA Testing\",\"BRCA1 BRCA2 Testing\",\"Breast Cancer Diagnostics\",\"Breast Cancer Molecular Testing\",\"NGS Breast Cancer\"],\"articleSection\":[\"Breast Cancer Molecular Testing\"],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa\",\"name\":\"Genes2Me\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g\",\"caption\":\"Genes2Me\"},\"description\":\"Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry\u2019s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics\u2014delivering integrated solutions that advance precision medicine and improve lives worldwide.\",\"sameAs\":[\"https:\/\/www.genes2me.com\/\"],\"url\":\"https:\/\/genes2me.com\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Breast Cancer Molecular Testing: NGS, BRCA & HRD","description":"Explore breast cancer molecular testing with NGS, BRCA1\/2, HRD assessment and ctDNA liquid biopsy for precision oncology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/","og_locale":"en_US","og_type":"article","og_title":"Breast Cancer Molecular Testing: NGS, BRCA & HRD","og_description":"Explore breast cancer molecular testing with NGS, BRCA1\/2, HRD assessment and ctDNA liquid biopsy for precision oncology.","og_url":"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/","og_site_name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","article_published_time":"2026-10-08T06:34:31+00:00","article_modified_time":"2026-10-08T07:48:22+00:00","og_image":[{"width":700,"height":525,"url":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2026\/10\/Breast-Cancer-1.jpg","type":"image\/jpeg"}],"author":"Genes2Me","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Genes2Me","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/genes2me.com\/blog\/#organization","name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","url":"https:\/\/genes2me.com\/blog\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg","contentUrl":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg","width":150,"height":69,"caption":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems"},"image":{"@id":"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/"}},{"@type":"WebSite","@id":"https:\/\/genes2me.com\/blog\/#website","url":"https:\/\/genes2me.com\/blog\/","name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","description":"Real Time PCR Molecular Diagnostics NGS Cancer Screening Sequencing COVID-19 Rapid Antigen Antibody Made in India Manufacturer Clinical\/Whole Exome","publisher":{"@id":"https:\/\/genes2me.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/genes2me.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/","url":"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/","name":"Breast Cancer Molecular Testing: NGS, BRCA & HRD","isPartOf":{"@id":"https:\/\/genes2me.com\/blog\/#website"},"datePublished":"2026-10-08T06:34:31+00:00","dateModified":"2026-10-08T07:48:22+00:00","description":"Explore breast cancer molecular testing with NGS, BRCA1\/2, HRD assessment and ctDNA liquid biopsy for precision oncology.","breadcrumb":{"@id":"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/genes2me.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Breast Cancer Awareness Month: Advancing Precision Testing Through Molecular Diagnostics"}]},{"@type":"Article","@id":"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/#article","isPartOf":{"@id":"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/"},"author":{"name":"Genes2Me","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa"},"headline":"Breast Cancer Awareness Month: Advancing Precision Testing Through Molecular Diagnostics","datePublished":"2026-10-08T06:34:31+00:00","dateModified":"2026-10-08T07:48:22+00:00","mainEntityOfPage":{"@id":"https:\/\/genes2me.com\/blog\/breast-cancer-molecular-testing\/"},"wordCount":1825,"publisher":{"@id":"https:\/\/genes2me.com\/blog\/#organization"},"keywords":["BRCA Testing","BRCA1 BRCA2 Testing","Breast Cancer Diagnostics","Breast Cancer Molecular Testing","NGS Breast Cancer"],"articleSection":["Breast Cancer Molecular Testing"],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa","name":"Genes2Me","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g","caption":"Genes2Me"},"description":"Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry\u2019s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics\u2014delivering integrated solutions that advance precision medicine and improve lives worldwide.","sameAs":["https:\/\/www.genes2me.com\/"],"url":"https:\/\/genes2me.com\/blog\/author\/admin\/"}]}},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/1117"}],"collection":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/comments?post=1117"}],"version-history":[{"count":5,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/1117\/revisions"}],"predecessor-version":[{"id":1137,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/1117\/revisions\/1137"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/media\/1125"}],"wp:attachment":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/media?parent=1117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/categories?post=1117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/tags?post=1117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}